NCT05742594View on ClinicalTrials.gov

A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

64

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

March 31, 2023

Study Completion Date

April 3, 2023

Conditions

Healthy

Interventions

DRUG

Lazertinib

Lazertinib will be administered orally.

Trial Locations (1)

85283

Celerion, Tempe

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY